NCT07080931
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
StatusCompleted
PhasePhase 3
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 27 words Show 5 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Dec 2027 to Jun 6, 2026
- Enrollment target: estimated 294 to confirmed 296
- Start date: Feb 24, 2025 to Mar 10, 2025
- Site details revised
- Notable Eligibility criteria revised
- Primary endpoint revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in Target Area Hair Count (TAHC) at Week 24, assessed via digital phototrichogram analysis in trial participa
Timeframe: Week 24
Secondary (3)
Mean change from baseline in Target Area Hair Count (TAHC) at Weeks 6, 12, and 18
Percent change from baseline in Target Area Hair Count (TAHC) at Weeks 12 and 24
Self-assessed satisfaction scores at Weeks 6, 12, 18, and 24
Arms and interventions
5% Minoxidil FoamExperimental
Placebo for 5% Minoxidil FoamPlacebo comparator
Drugs: 5% minoxidil foam, Placebo for 5% Minoxidil Foam
Sites
1 site in 1 country
- Beijing, ChinaBeijing, China